Changes in Markers of Collagen Metabolism at 1 month and final visit for participants randomized to spironolactone or control
| Serum Markers of Collagen Metabolism . | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| . | One month . | . | End of trial . | . | |||||
| . | Control . | Spironolactone . | . | P . | Control . | Spironolactone . | . | P . | |
| n . | 257 . | 259 . | . | . | 255 . | 251 . | . | . | |
| . | Mean (SD) change . | Mean difference (95% CI) . | . | Mean (SD) change . | Mean difference (95% CI) . | . | |||
| Galectin-3 μg/L | −0.13 (3.9) | +0.89 (4.8) | +1.06 (0.28 to 1.84) | =0.008 | +0.40 (4.4) | +1.55 (4.2) | +1.20 (0.43 to 1.96) | =0.002 | |
| PIIINP μg/L | −0.22 (1.9) | −0.19 (1.5) | −0.13 (−0.38 to 0.12) | =0.300 | −0.20 (2.0) | −0.15 (1.7) | −0.15 (−0.44 to 0.15) | 0.323 | |
| <Bas.Galectin-3 | −0.12 (1.8) | −0.30 (1.4) | −0.28 (−0.63 to 0.06) | Interaction =0.188 | −0.12 (2.0) | −0.16 (1.9) | −0.16 (−0.57 to 0.26) | Interaction 0.947 | |
| >Bas.Galectin-3 | −0.33 (1.9) | −0.07 (1.6) | +0.05 (−0.31 to 0.40) | −0.27 (2.1) | −0.15 (1.5) | −0.14 (−0.56 to 0.28) | |||
| PICP μg/L | 1.2 (18.1) | −4.0 (19.0) | −5.7 (−8.8 to −2.6) | <0.001 | −0.1 (21.5) | −7.3 (24.4) | −8.1 (−11.9 to −4.3) | <0.001 | |
| <Bas.Galectin-3 | 2.4 (18.1) | −3.0 (18.8) | −6.1 (−10.4 to −1.8) | Interaction =0.846 | −0.1 (20.1) | −5.1 (23.1) | −6.1 (−11.5 to −0.7) | Interaction =0.280 | |
| >Bas.Galectin-3 | 0.0 (18.2) | −5.2 (19.1) | −5.5 (−9.9 to −1.0) | −0.2 (22.9) | −9.8 (25.7) | −10.3 (−15.7 to −4.9) | |||
| CITP μg/L | +0.03 (0.2) | +0.10 (0.3) | +0.06 (0.01 to 0.10) | =0.010 | +0.03 (0.3) | +0.10 (0.4) | +0.06 (−0.00 to 0.12) | =0.065 | |
| <Bas.Galectin-3 | +0.01 (0.2) | +0.07 (0.3) | +0.05 (−0.01 to 0.11) | Interaction =0.723 | 0.00 (0.3) | +0.06 (0.4) | +0.04 (−0.04 to 0.13) | Interaction =0.539 | |
| >Bas.Galectin-3 | +0.06 (0.2) | +0.13 (0.3) | +0.07 (0.01 to 0.13) | +0.07 (0.4) | +0.15 (0.4) | +0.08 (−0.01 to 0.16) | |||
| PICP/CITP ratio | −0.3 (7.7) | −3.1 (9.7) | −2.6 (−4.0 to −1.3) | <0.001 | −0.7 (8.3) | −3.7 (10.1) | −2.9 (−4.3 to −1.5) | <0.001 | |
| <Bas.Galectin-3 | +0.7 (8.4) | −2.8 (11.0) | −3.1 (−4.9 to −1.3) | Interaction =0.573 | −0.3 (8.9) | −3.4 (11.6) | −2.4 (−4.4 to −0.4) | Interaction =0.442 | |
| >Bas.Galectin-3 | −1.3 (6.7) | −3.5 (8.0) | −2.3 (−4.2 to −0.4) | −1.0 (7.6) | −4.2 (8.3) | −3.5 (−5.5 to −1.5) | |||
| MMP-1 μg/L | −0.01 (0.2) | 0.00 (0.2) | 0.00 (−0.03 to 0.04) | 0.871 | −0.01 (0.3) | −0.01 (0.3) | 0.01 (−0.04 to 0.06) | 0.715 | |
| <Bas.Galectin-3 | −0.02 (0.2) | −0.01 (0.2) | +0.01 (−0.04 to 0.06) | Interaction =0.849 | 0.00 (0.3) | +0.01 (0.2) | −0.00 (−0.05 to 0.05) | Interaction =0.407 | |
| >Bas.Galectin-3 | +0.01 (0.2) | +0.01 (0.2) | 0.00 (−0.05 to 0.05) | −0.01 (0.2) | −0.03 (0.3) | −0.01 (−0.08 to 0.05) | |||
| Serum Markers of Collagen Metabolism . | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| . | One month . | . | End of trial . | . | |||||
| . | Control . | Spironolactone . | . | P . | Control . | Spironolactone . | . | P . | |
| n . | 257 . | 259 . | . | . | 255 . | 251 . | . | . | |
| . | Mean (SD) change . | Mean difference (95% CI) . | . | Mean (SD) change . | Mean difference (95% CI) . | . | |||
| Galectin-3 μg/L | −0.13 (3.9) | +0.89 (4.8) | +1.06 (0.28 to 1.84) | =0.008 | +0.40 (4.4) | +1.55 (4.2) | +1.20 (0.43 to 1.96) | =0.002 | |
| PIIINP μg/L | −0.22 (1.9) | −0.19 (1.5) | −0.13 (−0.38 to 0.12) | =0.300 | −0.20 (2.0) | −0.15 (1.7) | −0.15 (−0.44 to 0.15) | 0.323 | |
| <Bas.Galectin-3 | −0.12 (1.8) | −0.30 (1.4) | −0.28 (−0.63 to 0.06) | Interaction =0.188 | −0.12 (2.0) | −0.16 (1.9) | −0.16 (−0.57 to 0.26) | Interaction 0.947 | |
| >Bas.Galectin-3 | −0.33 (1.9) | −0.07 (1.6) | +0.05 (−0.31 to 0.40) | −0.27 (2.1) | −0.15 (1.5) | −0.14 (−0.56 to 0.28) | |||
| PICP μg/L | 1.2 (18.1) | −4.0 (19.0) | −5.7 (−8.8 to −2.6) | <0.001 | −0.1 (21.5) | −7.3 (24.4) | −8.1 (−11.9 to −4.3) | <0.001 | |
| <Bas.Galectin-3 | 2.4 (18.1) | −3.0 (18.8) | −6.1 (−10.4 to −1.8) | Interaction =0.846 | −0.1 (20.1) | −5.1 (23.1) | −6.1 (−11.5 to −0.7) | Interaction =0.280 | |
| >Bas.Galectin-3 | 0.0 (18.2) | −5.2 (19.1) | −5.5 (−9.9 to −1.0) | −0.2 (22.9) | −9.8 (25.7) | −10.3 (−15.7 to −4.9) | |||
| CITP μg/L | +0.03 (0.2) | +0.10 (0.3) | +0.06 (0.01 to 0.10) | =0.010 | +0.03 (0.3) | +0.10 (0.4) | +0.06 (−0.00 to 0.12) | =0.065 | |
| <Bas.Galectin-3 | +0.01 (0.2) | +0.07 (0.3) | +0.05 (−0.01 to 0.11) | Interaction =0.723 | 0.00 (0.3) | +0.06 (0.4) | +0.04 (−0.04 to 0.13) | Interaction =0.539 | |
| >Bas.Galectin-3 | +0.06 (0.2) | +0.13 (0.3) | +0.07 (0.01 to 0.13) | +0.07 (0.4) | +0.15 (0.4) | +0.08 (−0.01 to 0.16) | |||
| PICP/CITP ratio | −0.3 (7.7) | −3.1 (9.7) | −2.6 (−4.0 to −1.3) | <0.001 | −0.7 (8.3) | −3.7 (10.1) | −2.9 (−4.3 to −1.5) | <0.001 | |
| <Bas.Galectin-3 | +0.7 (8.4) | −2.8 (11.0) | −3.1 (−4.9 to −1.3) | Interaction =0.573 | −0.3 (8.9) | −3.4 (11.6) | −2.4 (−4.4 to −0.4) | Interaction =0.442 | |
| >Bas.Galectin-3 | −1.3 (6.7) | −3.5 (8.0) | −2.3 (−4.2 to −0.4) | −1.0 (7.6) | −4.2 (8.3) | −3.5 (−5.5 to −1.5) | |||
| MMP-1 μg/L | −0.01 (0.2) | 0.00 (0.2) | 0.00 (−0.03 to 0.04) | 0.871 | −0.01 (0.3) | −0.01 (0.3) | 0.01 (−0.04 to 0.06) | 0.715 | |
| <Bas.Galectin-3 | −0.02 (0.2) | −0.01 (0.2) | +0.01 (−0.04 to 0.06) | Interaction =0.849 | 0.00 (0.3) | +0.01 (0.2) | −0.00 (−0.05 to 0.05) | Interaction =0.407 | |
| >Bas.Galectin-3 | +0.01 (0.2) | +0.01 (0.2) | 0.00 (−0.05 to 0.05) | −0.01 (0.2) | −0.03 (0.3) | −0.01 (−0.08 to 0.05) | |||
<Bas., less than median serum galectin-3 at baseline; >Bas., greater than median serum galectin-3 at baseline; CITP, collagen type-1 C-terminal telopeptide; MMP-I, matrix metalloproteinase-1; NT-proBNP, amino-terminal B-type natriuretic peptide; PICP, procollagen type-I C-terminal pro-peptide; PIIINP, procollagen type-III N-terminal pro-peptide; SD, standard deviation.
Values shown in bold are significant at a P-value <0.05.
Changes in Markers of Collagen Metabolism at 1 month and final visit for participants randomized to spironolactone or control
| Serum Markers of Collagen Metabolism . | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| . | One month . | . | End of trial . | . | |||||
| . | Control . | Spironolactone . | . | P . | Control . | Spironolactone . | . | P . | |
| n . | 257 . | 259 . | . | . | 255 . | 251 . | . | . | |
| . | Mean (SD) change . | Mean difference (95% CI) . | . | Mean (SD) change . | Mean difference (95% CI) . | . | |||
| Galectin-3 μg/L | −0.13 (3.9) | +0.89 (4.8) | +1.06 (0.28 to 1.84) | =0.008 | +0.40 (4.4) | +1.55 (4.2) | +1.20 (0.43 to 1.96) | =0.002 | |
| PIIINP μg/L | −0.22 (1.9) | −0.19 (1.5) | −0.13 (−0.38 to 0.12) | =0.300 | −0.20 (2.0) | −0.15 (1.7) | −0.15 (−0.44 to 0.15) | 0.323 | |
| <Bas.Galectin-3 | −0.12 (1.8) | −0.30 (1.4) | −0.28 (−0.63 to 0.06) | Interaction =0.188 | −0.12 (2.0) | −0.16 (1.9) | −0.16 (−0.57 to 0.26) | Interaction 0.947 | |
| >Bas.Galectin-3 | −0.33 (1.9) | −0.07 (1.6) | +0.05 (−0.31 to 0.40) | −0.27 (2.1) | −0.15 (1.5) | −0.14 (−0.56 to 0.28) | |||
| PICP μg/L | 1.2 (18.1) | −4.0 (19.0) | −5.7 (−8.8 to −2.6) | <0.001 | −0.1 (21.5) | −7.3 (24.4) | −8.1 (−11.9 to −4.3) | <0.001 | |
| <Bas.Galectin-3 | 2.4 (18.1) | −3.0 (18.8) | −6.1 (−10.4 to −1.8) | Interaction =0.846 | −0.1 (20.1) | −5.1 (23.1) | −6.1 (−11.5 to −0.7) | Interaction =0.280 | |
| >Bas.Galectin-3 | 0.0 (18.2) | −5.2 (19.1) | −5.5 (−9.9 to −1.0) | −0.2 (22.9) | −9.8 (25.7) | −10.3 (−15.7 to −4.9) | |||
| CITP μg/L | +0.03 (0.2) | +0.10 (0.3) | +0.06 (0.01 to 0.10) | =0.010 | +0.03 (0.3) | +0.10 (0.4) | +0.06 (−0.00 to 0.12) | =0.065 | |
| <Bas.Galectin-3 | +0.01 (0.2) | +0.07 (0.3) | +0.05 (−0.01 to 0.11) | Interaction =0.723 | 0.00 (0.3) | +0.06 (0.4) | +0.04 (−0.04 to 0.13) | Interaction =0.539 | |
| >Bas.Galectin-3 | +0.06 (0.2) | +0.13 (0.3) | +0.07 (0.01 to 0.13) | +0.07 (0.4) | +0.15 (0.4) | +0.08 (−0.01 to 0.16) | |||
| PICP/CITP ratio | −0.3 (7.7) | −3.1 (9.7) | −2.6 (−4.0 to −1.3) | <0.001 | −0.7 (8.3) | −3.7 (10.1) | −2.9 (−4.3 to −1.5) | <0.001 | |
| <Bas.Galectin-3 | +0.7 (8.4) | −2.8 (11.0) | −3.1 (−4.9 to −1.3) | Interaction =0.573 | −0.3 (8.9) | −3.4 (11.6) | −2.4 (−4.4 to −0.4) | Interaction =0.442 | |
| >Bas.Galectin-3 | −1.3 (6.7) | −3.5 (8.0) | −2.3 (−4.2 to −0.4) | −1.0 (7.6) | −4.2 (8.3) | −3.5 (−5.5 to −1.5) | |||
| MMP-1 μg/L | −0.01 (0.2) | 0.00 (0.2) | 0.00 (−0.03 to 0.04) | 0.871 | −0.01 (0.3) | −0.01 (0.3) | 0.01 (−0.04 to 0.06) | 0.715 | |
| <Bas.Galectin-3 | −0.02 (0.2) | −0.01 (0.2) | +0.01 (−0.04 to 0.06) | Interaction =0.849 | 0.00 (0.3) | +0.01 (0.2) | −0.00 (−0.05 to 0.05) | Interaction =0.407 | |
| >Bas.Galectin-3 | +0.01 (0.2) | +0.01 (0.2) | 0.00 (−0.05 to 0.05) | −0.01 (0.2) | −0.03 (0.3) | −0.01 (−0.08 to 0.05) | |||
| Serum Markers of Collagen Metabolism . | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| . | One month . | . | End of trial . | . | |||||
| . | Control . | Spironolactone . | . | P . | Control . | Spironolactone . | . | P . | |
| n . | 257 . | 259 . | . | . | 255 . | 251 . | . | . | |
| . | Mean (SD) change . | Mean difference (95% CI) . | . | Mean (SD) change . | Mean difference (95% CI) . | . | |||
| Galectin-3 μg/L | −0.13 (3.9) | +0.89 (4.8) | +1.06 (0.28 to 1.84) | =0.008 | +0.40 (4.4) | +1.55 (4.2) | +1.20 (0.43 to 1.96) | =0.002 | |
| PIIINP μg/L | −0.22 (1.9) | −0.19 (1.5) | −0.13 (−0.38 to 0.12) | =0.300 | −0.20 (2.0) | −0.15 (1.7) | −0.15 (−0.44 to 0.15) | 0.323 | |
| <Bas.Galectin-3 | −0.12 (1.8) | −0.30 (1.4) | −0.28 (−0.63 to 0.06) | Interaction =0.188 | −0.12 (2.0) | −0.16 (1.9) | −0.16 (−0.57 to 0.26) | Interaction 0.947 | |
| >Bas.Galectin-3 | −0.33 (1.9) | −0.07 (1.6) | +0.05 (−0.31 to 0.40) | −0.27 (2.1) | −0.15 (1.5) | −0.14 (−0.56 to 0.28) | |||
| PICP μg/L | 1.2 (18.1) | −4.0 (19.0) | −5.7 (−8.8 to −2.6) | <0.001 | −0.1 (21.5) | −7.3 (24.4) | −8.1 (−11.9 to −4.3) | <0.001 | |
| <Bas.Galectin-3 | 2.4 (18.1) | −3.0 (18.8) | −6.1 (−10.4 to −1.8) | Interaction =0.846 | −0.1 (20.1) | −5.1 (23.1) | −6.1 (−11.5 to −0.7) | Interaction =0.280 | |
| >Bas.Galectin-3 | 0.0 (18.2) | −5.2 (19.1) | −5.5 (−9.9 to −1.0) | −0.2 (22.9) | −9.8 (25.7) | −10.3 (−15.7 to −4.9) | |||
| CITP μg/L | +0.03 (0.2) | +0.10 (0.3) | +0.06 (0.01 to 0.10) | =0.010 | +0.03 (0.3) | +0.10 (0.4) | +0.06 (−0.00 to 0.12) | =0.065 | |
| <Bas.Galectin-3 | +0.01 (0.2) | +0.07 (0.3) | +0.05 (−0.01 to 0.11) | Interaction =0.723 | 0.00 (0.3) | +0.06 (0.4) | +0.04 (−0.04 to 0.13) | Interaction =0.539 | |
| >Bas.Galectin-3 | +0.06 (0.2) | +0.13 (0.3) | +0.07 (0.01 to 0.13) | +0.07 (0.4) | +0.15 (0.4) | +0.08 (−0.01 to 0.16) | |||
| PICP/CITP ratio | −0.3 (7.7) | −3.1 (9.7) | −2.6 (−4.0 to −1.3) | <0.001 | −0.7 (8.3) | −3.7 (10.1) | −2.9 (−4.3 to −1.5) | <0.001 | |
| <Bas.Galectin-3 | +0.7 (8.4) | −2.8 (11.0) | −3.1 (−4.9 to −1.3) | Interaction =0.573 | −0.3 (8.9) | −3.4 (11.6) | −2.4 (−4.4 to −0.4) | Interaction =0.442 | |
| >Bas.Galectin-3 | −1.3 (6.7) | −3.5 (8.0) | −2.3 (−4.2 to −0.4) | −1.0 (7.6) | −4.2 (8.3) | −3.5 (−5.5 to −1.5) | |||
| MMP-1 μg/L | −0.01 (0.2) | 0.00 (0.2) | 0.00 (−0.03 to 0.04) | 0.871 | −0.01 (0.3) | −0.01 (0.3) | 0.01 (−0.04 to 0.06) | 0.715 | |
| <Bas.Galectin-3 | −0.02 (0.2) | −0.01 (0.2) | +0.01 (−0.04 to 0.06) | Interaction =0.849 | 0.00 (0.3) | +0.01 (0.2) | −0.00 (−0.05 to 0.05) | Interaction =0.407 | |
| >Bas.Galectin-3 | +0.01 (0.2) | +0.01 (0.2) | 0.00 (−0.05 to 0.05) | −0.01 (0.2) | −0.03 (0.3) | −0.01 (−0.08 to 0.05) | |||
<Bas., less than median serum galectin-3 at baseline; >Bas., greater than median serum galectin-3 at baseline; CITP, collagen type-1 C-terminal telopeptide; MMP-I, matrix metalloproteinase-1; NT-proBNP, amino-terminal B-type natriuretic peptide; PICP, procollagen type-I C-terminal pro-peptide; PIIINP, procollagen type-III N-terminal pro-peptide; SD, standard deviation.
Values shown in bold are significant at a P-value <0.05.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
